Sharath Subramanian1, Hamed Emami1, Esad Vucic1, Parmanand Singh1, Jayanthi Vijayakumar1, Kenneth M Fifer1, Achilles Alon2, Sudha S Shankar2, Michael Farkouh3, James H F Rudd4, Zahi A Fayad5, Thomas E Van Dyke6, Ahmed Tawakol7. 1. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2. Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey. 3. Peter Munk Cardiac Centre and the Heart and Stroke Richard Lewar Centre of Excellence, the University of Toronto, Toronto, Ontario, Canada. 4. Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom. 5. Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 6. Forsyth Institute, Cambridge, Massachusetts. 7. Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: atawakol@partners.org.
Abstract
OBJECTIVES: The purpose of this study was to test whether high-dose statin treatment would result in a reduction in periodontal inflammation as assessed by (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT). BACKGROUND: Periodontal disease (PD) is an independent risk factor for atherosclerosis. METHODS: Eighty-three adults with risk factors or with established atherosclerosis and who were not taking high-dose statins were randomized to atorvastatin 80 mg vs. 10 mg in a multicenter, double-blind trial to evaluate the impact of atorvastatin on arterial inflammation. Subjects were evaluated using FDG-PET/CT at baseline and at 4 and 12 weeks. Arterial and periodontal tracer activity was assessed while blinded to treatment allocation, clinical characteristics, and temporal sequence. Periodontal bone loss (an index of PD severity) was evaluated using contrast-enhanced CT images while blinded to clinical and imaging data. RESULTS: Seventy-one subjects completed the study, and 59 provided periodontal images for analysis. At baseline, areas of severe PD had higher target-to-background ratio (TBR) compared with areas without severe PD (mean TBR: 3.83 [95% confidence interval (CI): 3.36 to 4.30] vs. 3.18 [95% CI: 2.91 to 3.44], p = 0.004). After 12 weeks, there was a significant reduction in periodontal inflammation in patients randomized to atorvastatin 80 mg vs. 10 mg (ΔTBR 80 mg vs. 10 mg group: mean -0.43 [95% CI: -0.83 to -0.02], p = 0.04). Between-group differences were greater in patients with higher periodontal inflammation at baseline (mean -0.74 [95% CI: -1.29 to -0.19], p = 0.01) and in patients with severe bone loss at baseline (-0.61 [95% CI: -1.16 to -0.054], p = 0.03). Furthermore, the changes in periodontal inflammation correlated with changes in carotid inflammation (R = 0.61, p < 0.001). CONCLUSIONS: High-dose atorvastatin reduces periodontal inflammation, suggesting a newly recognized effect of statins. Given the concomitant changes observed in periodontal and arterial inflammation, these data raise the possibility that a portion of that beneficial impact of statins on atherosclerosis relate to reductions in extra-arterial inflammation, for example, periodontitis. (Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque; NCT00703261).
OBJECTIVES: The purpose of this study was to test whether high-dose statin treatment would result in a reduction in periodontal inflammation as assessed by (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT). BACKGROUND: Periodontal disease (PD) is an independent risk factor for atherosclerosis. METHODS: Eighty-three adults with risk factors or with established atherosclerosis and who were not taking high-dose statins were randomized to atorvastatin 80 mg vs. 10 mg in a multicenter, double-blind trial to evaluate the impact of atorvastatin on arterial inflammation. Subjects were evaluated using FDG-PET/CT at baseline and at 4 and 12 weeks. Arterial and periodontal tracer activity was assessed while blinded to treatment allocation, clinical characteristics, and temporal sequence. Periodontal bone loss (an index of PD severity) was evaluated using contrast-enhanced CT images while blinded to clinical and imaging data. RESULTS: Seventy-one subjects completed the study, and 59 provided periodontal images for analysis. At baseline, areas of severe PD had higher target-to-background ratio (TBR) compared with areas without severe PD (mean TBR: 3.83 [95% confidence interval (CI): 3.36 to 4.30] vs. 3.18 [95% CI: 2.91 to 3.44], p = 0.004). After 12 weeks, there was a significant reduction in periodontal inflammation in patients randomized to atorvastatin 80 mg vs. 10 mg (ΔTBR 80 mg vs. 10 mg group: mean -0.43 [95% CI: -0.83 to -0.02], p = 0.04). Between-group differences were greater in patients with higher periodontal inflammation at baseline (mean -0.74 [95% CI: -1.29 to -0.19], p = 0.01) and in patients with severe bone loss at baseline (-0.61 [95% CI: -1.16 to -0.054], p = 0.03). Furthermore, the changes in periodontal inflammation correlated with changes in carotid inflammation (R = 0.61, p < 0.001). CONCLUSIONS: High-dose atorvastatin reduces periodontal inflammation, suggesting a newly recognized effect of statins. Given the concomitant changes observed in periodontal and arterial inflammation, these data raise the possibility that a portion of that beneficial impact of statins on atherosclerosis relate to reductions in extra-arterial inflammation, for example, periodontitis. (Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque; NCT00703261).
Authors: Elena Figuero; María Sánchez-Beltrán; Susana Cuesta-Frechoso; Jose María Tejerina; Jose Antonio del Castro; Jose María Gutiérrez; David Herrera; Mariano Sanz Journal: J Periodontol Date: 2011-03-29 Impact factor: 6.993
Authors: Ahmed Tawakol; Raymond Q Migrino; Gregory G Bashian; Shahinaz Bedri; David Vermylen; Ricardo C Cury; Denise Yates; Glenn M LaMuraglia; Karen Furie; Stuart Houser; Henry Gewirtz; James E Muller; Thomas J Brady; Alan J Fischman Journal: J Am Coll Cardiol Date: 2006-10-17 Impact factor: 24.094
Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245
Authors: Zahi A Fayad; Venkatesh Mani; Mark Woodward; David Kallend; Markus Abt; Tracy Burgess; Valentin Fuster; Christie M Ballantyne; Evan A Stein; Jean-Claude Tardif; James H F Rudd; Michael E Farkouh; Ahmed Tawakol Journal: Lancet Date: 2011-09-09 Impact factor: 79.321
Authors: Daniel W Groves; Mori J Krantz; John E Hokanson; Lonnie R Johnson; Robert H Eckel; Gregory L Kinney; Marian Rewers; Janet K Snell-Bergeon; Amy C Alman Journal: Am J Cardiol Date: 2015-06-24 Impact factor: 2.778
Authors: Hatice Hasturk; Rima Abdallah; Alpdogan Kantarci; Daniel Nguyen; Nicholas Giordano; James Hamilton; Thomas E Van Dyke Journal: Arterioscler Thromb Vasc Biol Date: 2015-03-19 Impact factor: 8.311
Authors: James A Hamilton; Hatice Hasturk; Alpdogan Kantarci; Charles N Serhan; Thomas Van Dyke Journal: Curr Atheroscler Rep Date: 2017-11-06 Impact factor: 5.113
Authors: Oelisoa M Andriankaja; James J Jiménez; Francisco J Muñoz-Torres; Cynthia M Pérez; José L Vergara; Kaumudi J Joshipura Journal: J Clin Periodontol Date: 2015-12-11 Impact factor: 8.728